Status:
COMPLETED
Intravitreal Adalimumab in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration
Lead Sponsor:
Hospital Universitari Vall d'Hebron Research Institute
Conditions:
Age-Related Macular Degeneration
Choroidal Neovascularization
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Adalimumab is a humanized recombinant monoclonal antibody fragment targeted against tumor necrosis factor. This study will assess the safety and efficacy of intravitreal adalimumab administered in pat...
Eligibility Criteria
Inclusion
- \- Choroidal neovascularization secondary to age-related macular degeneration non-responders to the conventional treatment with ranibizumab (active choroidal neovascularization after loading phase of one injection per month for three consecutive months, followed by a maintenance phase with 5 injections in the last 12 months or 3 injections in the last 6 months
Exclusion
- Only one functional eye
- Hypersensitivity to adalimumab or any component of the formulation
- Previous systemic treatment with adalimumab
- Cancer
- Life expectancy \<1 year
Key Trial Info
Start Date :
May 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2011
Estimated Enrollment :
5 Patients enrolled
Trial Details
Trial ID
NCT01136252
Start Date
May 1 2010
End Date
October 1 2011
Last Update
March 19 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Servicio de Oftalmologia. Hospital Universitario Vall d'Hebron
Barcelona, Barcelona, Spain, 08035